Dec 20 (Reuters) - Factor Therapeutics Ltd:
* Factor Therapeutics announces commencement of phase II trial of a novel topical biologic for the treatment of chronic wounds
* Factor Therapeutics- company plans to provide an enrolment update in Q1 2017, and is targeting a top-line read-out of efficacy by Q4 2017 for vf001 Source text for Eikon: Further company coverage: FTT.AX